Opendata, web and dolomites

EULAT Eradicate GBC SIGNED

Establishment and Exploitation of a European-Latin American Research Consortium towards Eradication of Preventable Gallbladder Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EULAT Eradicate GBC project word cloud

Explore the words cloud of the EULAT Eradicate GBC project. It provides you a very rough idea of what is the project "EULAT Eradicate GBC" about.

national    secondary    american    genomic    efficient    prevention    industry    disease    score    refine    latin    constitute    benefit    platform    mechanisms    permit    huge    therapy    patients    behavioural    preventive    translational    adequately    omics    decisions    clinical    molecular    alterations    functionally    participation    differences    multifactorial    individuals    ethnic    link    individualized    primary    generation    gallbladder    tertiary    risk    cultural    accuracy    policies    significantly    medicine    causal    identification    plan    biomarkers    unravel    training    trials    considering    geographical    detection    removal    guiding    regions    cancer    epidemiological    prediction    prime    estimation    lifestyle    surveillance    personalized    incorporation    integrates    incidence    gender    precision    gbc    generate    data    environmental    newly    resource    individual    guarantees    pave    incidental    health    validate    biorepository   

Project "EULAT Eradicate GBC" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITATSKLINIKUM HEIDELBERG 

Organization address
address: IM NEUENHEIMER FELD 672
city: HEIDELBERG
postcode: 69120
website: www.klinikum.uni-heidelberg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 4˙675˙932 €
 EC max contribution 4˙675˙932 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2025-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) coordinator 2˙362˙344.00
2    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 762˙500.00
3    UNIVERSIDAD DE CHILE CL (SANTIAGO) participant 571˙000.00
4    UNIVERSITY OF BRISTOL UK (BRISTOL) participant 126˙337.00
5    INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN PE (LIMA) participant 125˙000.00
6    SANATORIO EL CARMEN SA AR (SALTA) participant 125˙000.00
7    Universidad Austral de Chile CL (VALDIVIA) participant 125˙000.00
8    UNIVERSIDAD CATÓLICA DEL MAULE CL (TALCA) participant 125˙000.00
9    UNIVERSIDAD DE LA FRONTERA CL (TEMUCO) participant 125˙000.00
10    UNIVERSIDAD MAYOR DE SAN SIMON BO (COCHABAMBA) participant 125˙000.00
11    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 62˙500.00
12    KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET DE (FRANKFURT AM MAIN) participant 41˙250.00
13    CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER FR (LYON CEDEX 08) participant 0.00

Map

 Project objective

Gallbladder cancer (GBC) is a neglected disease with huge potential for prevention. This project aims at significantly improving the accuracy of risk estimation and early detection of GBC by identifying and adequately considering geographical, environmental, lifestyle, ethnic, gender and molecular differences. We plan to generate the information needed to establish and refine current prevention programmes, including the primary, secondary and tertiary prevention of GBC. We will (1) build a unique European–Latin American GBC biorepository integrated into a tailored IT platform, (2) identify, validate and functionally characterize novel GBC biomarkers, (3) develop a multifactorial risk score that integrates established and newly identified epidemiological and molecular risk factors, (4) improve the understanding of the causal mechanisms that link lifestyle, cultural and behavioural factors to GBC development, (5) unravel novel opportunities for the targeted therapy of incidental GBC, (6) exploit existing and newly generated epidemiological and multi-omics data to improve the accuracy of GBC risk prediction and (7) contribute to the training of the next generation of Latin American researchers in precision medicine for GBC. The generated information will permit identification of individuals at high GBC risk, guiding surveillance and individual decisions on the possible benefit of preventive gallbladder removal in regions of low and high GBC incidence. Novel data on genomic alterations in incidental GBC will pave the way towards implementation of future clinical trials. The planned European–Latin American GBC biorepository and IT platform will constitute a prime resource for translational research on individualized prevention, personalized early detection and targeted therapy of GBC. The participation in our project of representatives of health authorities, patients and the industry guarantees the efficient incorporation of project results into national health policies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EULAT ERADICATE GBC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EULAT ERADICATE GBC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More